Scorpius Holdings, Inc. Announces Closing of Public Offering
May 16, 2024 16:15 ET
|
Scorpius Holdings, Inc.
DURHAM, N.C., May 16, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO),...
Fortrea Appoints Machelle Sanders to Board of Directors
May 16, 2024 16:05 ET
|
Fortrea Holdings Inc
DURHAM, N.C., May 16, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the appointment of Machelle Sanders to...
Scorpius Holdings Commends Congress on Bipartisan Legislative Action Aimed at Bolstering U.S. Biomanufacturing
May 16, 2024 08:00 ET
|
Scorpius Holdings, Inc.
DURHAM, N.C., May 16, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization providing...
Scorpius Holdings Achieves Major Milestone with cGMP Facility Validation for Microbial Manufacturing
May 15, 2024 08:00 ET
|
Scorpius Holdings, Inc.
DURHAM, N.C., May 15, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO),...
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
May 14, 2024 08:00 ET
|
Tenax Therapeutics
Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF ...
Tavros Therapeutics Achieves Two Milestone Payments in its Collaboration with Vividion Therapeutics
May 14, 2024 07:30 ET
|
Tavros Therapeutics
DURHAM, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- Tavros Therapeutics, Inc., a precision oncology platform company, today announced that the Company has achieved two milestone payments in its...
Scorpius Holdings, Inc. Announces Pricing of Public Offering
May 14, 2024 07:15 ET
|
Scorpius Holdings, Inc.
DURHAM, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius”, or the “Company”), an integrated contract development and manufacturing organization...
BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology
May 14, 2024 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the...
ElevateBio Announces New U.S. Patents for Lead Life Edit CRISPR Systems and Adenine Deaminases Enabling Advanced Gene Editing Techniques
May 14, 2024 07:00 ET
|
ElevateBio
- Issued patents provide protection for multiple of Life Edit’s lead adenine deaminases, base editors, and RNA-guided nucleases with applications in base editing and reverse transcriptase editing - ...
Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 06:03 ET
|
Fennec Pharmaceuticals Inc.
~ Achieved First Quarter 2024 Total Net Revenues of $25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction ~ ~ Executed Exclusive Licensing Agreement...